CYTK250117C115000
- 1.25
- 0.000.00%
Cytokinetics Newsroom
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $120
Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating
Truist Financial Sticks to Their Buy Rating for Cytokinetics (CYTK)
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $120
Cytokinetics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.
RBC Capital Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $82
Cytokinetics Analyst Ratings
RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $82
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $62 to $120
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), PTC Therapeutics (PTCT) and Vir Biotechnology (VIR)
Cytokinetics Price Target Maintained With a $72.00/Share by Needham
Cytokinetics Analyst Ratings
Promising Prospects for Cytokinetics: Aficamten's Strong Phase 3 Results and Strategic Bayer Collaboration Drive Buy Rating
RBC Capital Sticks to Its Buy Rating for Cytokinetics (CYTK)
Mizuho Maintains Outperform on Cytokinetics, Raises Price Target to $103
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $70 to $120
Cytokinetics' Hold Rating Amid Bayer Partnership and Acquisition Uncertainty
Cytokinetics Gains 'Buy' Rating Due to Strategic Collaborations and Potential FDA Approval
Cytokinetics Analyst Ratings
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $120